Literature DB >> 18506386

Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment.

R Ghidoni1, L Benussi, M Glionna, M Franzoni, D Geroldi, E Emanuele, G Binetti.   

Abstract

Growing evidence advanced the idea that the soluble form of the receptor for advanced glycation end-products (sRAGE) might serve as a risk marker for several disorders including Alzheimer disease. We found a reduced level of circulating sRAGE in patients with mild cognitive impairment (MCI). The reduction of sRAGE in MCI, as well as the anticipation of the disease in patients with the lowest sRAGE levels (<or=225 pg/ml), suggest a role of the RAGE axis in the pathogenesis of the disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18506386     DOI： 10.1007/s00702-008-0069-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  13 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans.

Authors:  Diego Geroldi; Colomba Falcone; Piercarlo Minoretti; Enzo Emanuele; Mariarosa Arra; Angela D'Angelo
Journal:  J Am Geriatr Soc       Date:  2006-07       Impact factor: 5.562

3.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

Review 4.  Understanding RAGE, the receptor for advanced glycation end products.

Authors:  Angelika Bierhaus; Per M Humpert; Michael Morcos; Thoralf Wendt; Triantafyllos Chavakis; Bernd Arnold; David M Stern; Peter P Nawroth
Journal:  J Mol Med (Berl)       Date:  2005-08-24       Impact factor: 4.599

Review 5.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

6.  Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

Authors:  Enzo Emanuele; Angela D'Angelo; Carmine Tomaino; Giuliano Binetti; Roberta Ghidoni; Pierluigi Politi; Livia Bernardi; Raffaele Maletta; Amalia C Bruni; Diego Geroldi
Journal:  Arch Neurol       Date:  2005-11

7.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

Review 8.  Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide.

Authors:  S D Yan; A Roher; M Chaney; B Zlokovic; A M Schmidt; D Stern
Journal:  Biochim Biophys Acta       Date:  2000-07-26

Review 9.  Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

Authors:  Diego Geroldi; Colomba Falcone; Enzo Emanuele
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 10.  RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease.

Authors:  L G Bucciarelli; T Wendt; L Rong; E Lalla; M A Hofmann; M T Goova; A Taguchi; S F Yan; S D Yan; D M Stern; A M Schmidt
Journal:  Cell Mol Life Sci       Date:  2002-07       Impact factor: 9.261
View more
  22 in total

Review 1.  The association of diabetes and dementia and possible implications for nondiabetic populations.

Authors:  Ramit Ravona-Springer; Michal Schnaider-Beeri
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

Review 2.  Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.

Authors:  Douglas Walker; Lih Fen Lue; Gaurav Paul; Amar Patel; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2015-01-14       Impact factor: 6.206

3.  Detection of the receptor for advanced glycation endproducts in neuronally-derived exosomes in plasma.

Authors:  Sierra A Patterson; Gagan Deep; Tina E Brinkley
Journal:  Biochem Biophys Res Commun       Date:  2018-04-30       Impact factor: 3.575

4.  Structural basis for ligand recognition and activation of RAGE.

Authors:  Michael Koch; Seth Chitayat; Brian M Dattilo; Andre Schiefner; Joachim Diez; Walter J Chazin; Günter Fritz
Journal:  Structure       Date:  2010-10-13       Impact factor: 5.006

5.  Association between the RAGE G82S polymorphism and Alzheimer's disease.

Authors:  Keshen Li; Dawei Dai; Bin Zhao; Lifen Yao; Songpo Yao; Binyou Wang; Ze Yang
Journal:  J Neural Transm (Vienna)       Date:  2009-11-10       Impact factor: 3.575

6.  Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment.

Authors:  Tanja Hochstrasser; Elisabeth Weiss; Josef Marksteiner; Christian Humpel
Journal:  Exp Gerontol       Date:  2009-10-29       Impact factor: 4.032

7.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

Review 8.  Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.

Authors:  Ling Zhang; Rolf Postina; Yingqun Wang
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

9.  Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease.

Authors:  Nitin Mahajan; Namita Malik; Ajay Bahl; Yashpaul Sharma; Veena Dhawan
Journal:  Mol Cell Biochem       Date:  2009-05-02       Impact factor: 3.396

Review 10.  Soluble forms of RAGE in internal medicine.

Authors:  Natale Vazzana; Francesca Santilli; Chiara Cuccurullo; Giovanni Davì
Journal:  Intern Emerg Med       Date:  2009-09-02       Impact factor: 3.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.